Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.13 USD | +1.80% | +8.19% | -15.03% |
04-04 | Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing | MT |
04-04 | Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing | MT |
Business Summary
Number of employees: 436
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Genetic Medicines
100.0
%
| 61 | 100.0 % | 378 | 100.0 % | +520.01% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 61 | 100.0 % | 378 | 100.0 % | +520.01% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
John Evans
CEO | Chief Executive Officer | 46 | 31/12/16 |
President | 55 | 31/01/18 | |
Director of Finance/CFO | 47 | 31/07/19 | |
Gopi Shanker
CTO | Chief Tech/Sci/R&D Officer | - | 20/03/23 |
Amy Simon
CTO | Chief Tech/Sci/R&D Officer | - | 14/03/21 |
Manmohan Singh
CTO | Chief Tech/Sci/R&D Officer | 59 | 30/06/18 |
Brian Riley
PRN | Corporate Officer/Principal | 47 | 31/08/19 |
Susan O'Connor
HRO | Human Resources Officer | 61 | 31/07/17 |
Christine Bellon
LAW | General Counsel | - | 31/03/19 |
Suzanne Fleming
AUD | Comptroller/Controller/Auditor | 63 | 31/01/19 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Graham Cooper
BRD | Director/Board Member | 54 | 09/10/19 |
John Maraganore
BRD | Director/Board Member | 60 | 04/11/21 |
Mark Fishman
BRD | Director/Board Member | 72 | 30/04/18 |
Kristina Burow
BRD | Director/Board Member | 50 | 31/05/17 |
Director/Board Member | 68 | 09/01/21 | |
John Evans
CEO | Chief Executive Officer | 46 | 31/12/16 |
Christi L. Shaw
BRD | Director/Board Member | 57 | 12-13 |
Carole Ho
BRD | Director/Board Member | 51 | 14/11/18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 82,310,167 | 80,795,167 ( 98.16 %) | 0 | 98.16 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
PRIME MEDICINE, INC. 1.34% | 1,608,337 | 1.34% | 11,258,359 $ |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.03% | 1.8B | |
+25.69% | 48.09B | |
+46.90% | 40.62B | |
-3.46% | 40.43B | |
-6.20% | 28.36B | |
+9.17% | 24.89B | |
-20.42% | 19.01B | |
+28.07% | 12.09B | |
+0.17% | 11.88B | |
-1.24% | 11.8B |
- Stock Market
- Equities
- BEAM Stock
- Company Beam Therapeutics Inc.